Terkko Navigator / BioDrugs

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Doubl

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria

Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera® ) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study

Acknowledgement to Referees

Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

The Therapeutic Potential of Nanobodies

Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar

Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics

Delivering on the Promise of Biosimilars

Comment on:“Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”

Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”

Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically

In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study

Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product

CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms

Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP)

Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar

Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis

Evolution of the EU Biosimilar Framework: Past and Future

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications

Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer

An Efficient Development Paradigm for Biosimilars

Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?

The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks

Comment on“Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”

Oncolytic Viruses: Priming Time for Cancer Immunotherapy

Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy

Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Review of Current Status

Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine

Prediction of Immunogenicity of Therapeutic Proteins: Validity of Computational Tools

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy

Therapeutic Potential of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitors in Polycystic Kidney Disease

Application of Glatiramer Acetate to Neurodegenerative Diseases beyond Multiple Sclerosis: The Need for Disease-Specific Approaches

Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived Pharmaceuticals

Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

Selective Targeting of Cancer Stem Cells: A New Concept in Cancer Therapeutics

RNAi Therapy for HIV Infection: Principles and Practicalities

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil): Profile Report